Sun Pharmaceuticals (Sun Pharma) experienced a 5% decline in its stock price on the Bombay Stock Exchange, trading at ₹1,647.35, following profit booking by investors. This drop comes as the company moves to finalize a $12 billion acquisition of Organon & Co., which would mark the largest overseas merger and acquisition by an Indian pharmaceutical company. However, analysts are apprehensive about the deal due to Organon's $8 billion debt and competitive challenges in its operational segments, which include women's health and biosimilars. Additionally, the impending 100% tariffs on patented drugs proposed by the U.S. government could further complicate Sun Pharma's market strategy, as most of its products are manufactured outside the U.S. Analysts from HDFC Securities and Nomura have given a 'Buy' rating on Sun Pharma, projecting a target price of ₹2,000 per share, despite the potential adverse impacts of tariffs on earnings and market share. The stock is currently showing a bearish trend, with immediate support near ₹1,600 and resistance around ₹1,700.